Evolus, Inc. (NASDAQ:EOLS – Free Report) – Analysts at HC Wainwright issued their FY2029 EPS estimates for Evolus in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst D. Tsao anticipates that the company will earn $4.43 per share for the year. HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.63) per share.
Separately, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Tuesday.
Evolus Trading Down 0.8 %
Shares of EOLS opened at $14.02 on Thursday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The firm has a 50-day moving average price of $11.75 and a 200 day moving average price of $13.75. The firm has a market capitalization of $887.75 million, a P/E ratio of -15.41 and a beta of 1.32.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Essex Investment Management Co. LLC boosted its stake in Evolus by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock worth $4,788,000 after buying an additional 1,111 shares during the period. Creative Planning boosted its stake in Evolus by 23.7% during the third quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after buying an additional 2,963 shares during the period. Sei Investments Co. boosted its stake in shares of Evolus by 9.8% in the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock valued at $367,000 after purchasing an additional 3,020 shares during the period. KBC Group NV purchased a new position in shares of Evolus in the fourth quarter valued at approximately $49,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Evolus by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock valued at $197,000 after purchasing an additional 4,780 shares during the period. Hedge funds and other institutional investors own 90.69% of the company’s stock.
Evolus Company Profile
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
- Five stocks we like better than Evolus
- How to trade using analyst ratings
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Dividend Payout Ratio Calculator
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.